# Oral Semaglutide for Alcohol Use Disorder: The Phase 2 Trial's Missed Endpoint

A phase 2 trial of oral semaglutide in 50 adults with alcohol use disorder missed its primary craving outcome | heavy drinking days fell on a secondary measure, b −0.580.

Publisher: Buy This GLP Editorial Team
Canonical: https://buythisglp.com/research/semaglutide-alcohol-use-disorder-trial
Updated: 2026-11-15
Published: 2026-09-16

[← Research](https://buythisglp.com/research)

Evidence

# Oral Semaglutide for Alcohol Use Disorder: The Phase 2 Trial's Missed Endpoint

In 50 adults with moderate-to-severe alcohol use disorder, oral semaglutide did not reduce lab cue-elicited craving, the outcome the trial was built around. Heavy drinking days fell on a secondary measure.

Editorial profile: [Wesley Jenkins](https://buythisglp.com/authors/wesley-jenkins)[Buy This GLP Editorial Team](https://buythisglp.com/about)September 20264 min readUpdated November 2026

Primary outcome — lab cue-elicited craving, week 6 · Not significant. Drinks per day: not significant either. · Secondary and exploratory outcomes, each row on its own scale · upper bound · no effect · Heavy drinking days · −0.148 · Drinks per drinking day · −0.047 · Naturalistic craving · −0.216

**Research, not medical advice.** Buy This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://buythisglp.com/methodology) and [terms](https://buythisglp.com/terms).

## Key takeaways

-   A phase 2 double-blind trial in 50 adults with moderate-to-severe alcohol use disorder.
-   Oral semaglutide 3 mg daily for four weeks, then 7 mg daily for four weeks, against placebo.
-   The prespecified primary outcome — lab cue-elicited craving at week 6 — was not significant.
-   Drinks per day was not significant either.
-   Heavy drinking days fell, b −0.580, 95% CI −1.012 to −0.148. That is a secondary outcome.

## What the oral trial measured

Our [review of alcohol and tirzepatide](https://buythisglp.com/research/can-you-drink-alcohol-while-taking-tirzepatide) addresses a different drug and a different question. The trial here tested semaglutide for alcohol use disorder.

Schacht and colleagues randomized 50 treatment-seeking adults to oral semaglutide or placebo for eight weeks. At week six, the groups did not differ significantly on the primary craving measure after exposure to a preferred drink. The adjusted difference was −0.614 points (95% confidence interval −3.563 to 2.335) [\[1\]](https://buythisglp.com/research/semaglutide-alcohol-use-disorder-trial#ref-1).

In the last four weeks, the semaglutide group reported fewer heavy drinking days on a prespecified secondary outcome. The adjusted model coefficient was −0.580 (95% confidence interval −1.012 to −0.148). The difference in drinks per calendar day did not reach statistical significance [\[1\]](https://buythisglp.com/research/semaglutide-alcohol-use-disorder-trial#ref-1).

Drinks per drinking day and craving in daily life fell on exploratory measures. The trial used a different questionnaire for daily craving than for the primary laboratory measure. The researchers reported confidence intervals without adjusting for multiple comparisons, so the exploratory findings need confirmation [\[1\]](https://buythisglp.com/research/semaglutide-alcohol-use-disorder-trial#ref-1).

## What the injection trial adds

A separate trial recruited 108 adults with alcohol use disorder and obesity. Both groups received cognitive behavioral therapy. After 26 weeks, the share of heavy drinking days fell 13.7 percentage points more with weekly semaglutide injections than with placebo (95% confidence interval 5.4 to 22.0 points more)[\[2\]](https://buythisglp.com/research/semaglutide-alcohol-use-disorder-trial#ref-2).

Studies of [GLP-1 medicines for opioid use disorder](https://buythisglp.com/research/do-glp1-drugs-help-opioid-use-disorder) ask a different treatment question and use different outcome measures. Even within alcohol research, the injection trial measured heavy drinking days in adults with obesity and the oral trial prioritized a craving score. The two trials cannot establish whether one formulation works better for alcohol use disorder.

The oral trial followed participants for only eight weeks. Its results leave open whether any effect persists on longer treatment or after stopping [\[1\]](https://buythisglp.com/research/semaglutide-alcohol-use-disorder-trial#ref-1).

## Frequently asked

Did semaglutide reduce drinking in this trial?

Heavy drinking days fell on a prespecified secondary measure. The trial did not find a statistically significant difference in its primary lab craving measure or in drinks per calendar day.

Why does a primary outcome matter more than the others?

The primary outcome is chosen before the trial begins and guides the study design. The oral trial did not adjust for multiple comparisons, making its exploratory findings less certain.

How large was the trial?

The oral phase 2 trial randomized 50 adults and followed them for eight weeks. The separate injection trial included 108 adults with both alcohol use disorder and obesity.

What did the authors conclude?

That continued development is warranted. That is a call for a larger trial, not a finding that the drug works for alcohol use disorder.

## Sources

1.  \[1\] Schacht JP, et al. (2026). Oral Semaglutide for Alcohol Use Disorder: A Randomized Clinical Trial The American Journal of Psychiatry. [PMID 42522065](https://pubmed.ncbi.nlm.nih.gov/42522065/)
2.  \[2\] Klausen MK, et al. (2026). Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial The Lancet. [PMID 42070571](https://pubmed.ncbi.nlm.nih.gov/42070571/)

## Where to get it

### Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

[Open the price desk →](https://buythisglp.com/)

## More in Evidence

-   [
    
    50,678 adults with a BMI of 30 or more · Prescribed · 8.0% · Filled · 4.4% · Outlined bar runs to 10%. Medicaid had lower odds of both.
    
    ### Does Medicaid Cover Weight Loss Drugs? It Depends on Your State
    
    ](https://buythisglp.com/research/does-medicaid-cover-weight-loss-drugs)
-   [
    
    What the claim rests on · Sleep study · AHI 15 or more · Obesity · BMI 30 or more · Prescription · for sleep apnea · Part D claim · plan review · Trial thresholds shown. Your plan sets its approval requirements.
    
    ### Does Medicare Cover Zepbound for Sleep Apnea? The Diagnosis Is the Key
    
    ](https://buythisglp.com/research/does-medicare-cover-zepbound-for-sleep-apnea)
-   [
    
    Illustrative decline with a one-week half-life · Ozempic window: up to 5 days late · 100% · day 0 · 82% · day 2 · 67% · day 4 · 61% · day 5 · 50% · day 7 · A calculation from the label half-life, not a blood test.
    
    ### What Happens If You Miss a Dose of Ozempic? A Week-Long Half-Life Buys Time
    
    ](https://buythisglp.com/research/what-happens-if-you-miss-a-dose-of-ozempic)
